Click on a filter below to refine your search. Remove a filter to broaden your search.
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Risks for new-onset psychiatric diagnoses and anxiety disorders, but not mood disorders, increased in the early postacute phase.
The FDA received licensing applications sooner and had shorter review times compared with the European Medicines Agency.
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
The authors say that the review findings are limited by heterogenous definitions of long COVID in published studies.
Those who walked for exercise had a reduced likelihood of new frequent knee pain and medial joint space narrowing.
Compared with placebo, normalization of C-reactive protein and oxygen saturation was faster, with improvements seen on day 3 of treatment.
No deaths have been reported in either the U.S. or other countries affected by monkeypox outbreaks.